Carlo Rizzuto, Ph.D., is a Managing Director based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (sale), Repare (2020 IPO), Century Therapeutics (2021 IPO), Graphite Bio (2021 IPO), Jnana, 858 Therapeutics and Stablix. Carlo has been instrumental in establishing Versant’s presence in the Northeast. Prior to opening the NYC office, he was based in Versant’s Basel office.

• 

  Managing Director in Versant Ventures

  HARNESSING THE POWER OF SCIENCE, GLOBALLY